StreetInsider.com News Articles

Daré Bioscience gets $908K NIH grant for preterm birth program

Mon, 31 Aug 2026 08:44:31 -0400

Daré Bioscience, Inc. (NASDAQ: DARE) announced it received a notice of award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the National Institutes of Health (NIH), for approximately $908,000 to support its DARE-PTB2 program aimed at preventing preterm birth.

The award will fund one year of preclinical development. The notice also includes recommended future-year support of approximately $1.3 million for completion of initial preclinical pharmacokinetic, safety, and toxicity studies, though that additional funding is not guaranteed.

DARE-PTB2 is an early-stage investigational program targeting idiopathic preterm birth, defined as birth before 37 weeks of

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

Mon, 31 Aug 2026 08:44:00 -0400

New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million

DARE-PTB2 is an early-stage, investigational program focused on developing a potential new therapeutic approach for the prevention of preterm birth

SAN DIEGO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it received a new notice of award from the Eunice Kennedy Shriver National

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

Mon, 31 Aug 2026 08:44:00 -0400

New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million

DARE-PTB2 is an early-stage, investigational program focused on developing a potential new therapeutic approach for the prevention of preterm birth

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

Mon, 31 Aug 2026 08:44:00 -0400

New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million

DARE-PTB2 is an early-stage, investigational program focused on developing a potential new therapeutic approach for the prevention of preterm birth

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

Mon, 31 Aug 2026 08:44:00 -0400

New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million

DARE-PTB2 is an early-stage, investigational program focused on developing a potential new therapeutic approach for the prevention of preterm birth

Form SCHEDULE 13G Dare Bioscience, Inc. Filed by: Lind Global Fund III LP

Fri, 28 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260828/26997723.html

Form SCHEDULE 13G Dare Bioscience, Inc. Filed by: Lind Global Fund III LP

Fri, 28 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260828/26997723.html

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series

Thu, 27 Aug 2026 09:01:00 -0400

Video webcast now available here

SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it participated in the Virtual Investor “Why Now” on-demand series.

For the webcast, Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, presented the Company's investment thesis, highlighting its mission to advance innovative solutions that address significant unmet needs in women's health

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series

Thu, 27 Aug 2026 09:01:00 -0400

Video webcast now available here

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series

Thu, 27 Aug 2026 09:01:00 -0400

Video webcast now available here

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series

Thu, 27 Aug 2026 09:01:00 -0400

Video webcast now available here

Form S-1 Dare Bioscience, Inc.

Wed, 26 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260826/26982817.html

Form S-1 Dare Bioscience, Inc.

Wed, 26 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260826/26982817.html

Daré Bioscience publishes sildenafil cream Phase 1 data in menopause journal

Wed, 26 Aug 2026 08:45:58 -0400

Daré Bioscience, Inc. (NASDAQ: DARE) announced the publication of Phase 1 clinical study results for its topical sildenafil cream, 3.6%, in Menopause - The Journal of The Menopause Society. The study evaluated the safety and pharmacokinetics of the formulation in healthy postmenopausal women.

The open-label, within-participant dose-escalation study enrolled 21 healthy postmenopausal women with a mean age of 57. Participants received a single dose of placebo cream followed by escalating doses containing 50 mg, 100 mg, and 200 mg of sildenafil citrate, with a 14- to 16-day washout period between doses. Nineteen participants completed all four treatment periods.

All evaluated doses were

Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society

Wed, 26 Aug 2026 08:45:00 -0400

Daré’s proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposure

Company continues activities necessary to advance its Sildenafil Cream toward the FDA’s 505(b)(2) regulatory pathway* while in parallel launching DARE to PLAY™ Sildenafil Cream, the 503B compounded version of its proprietary sildenafil cream formulation**

DARE to PLAY Sildenafil Cream prescription dispensing and initial product revenue expected to commence in Q3 2026

SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience,

Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society

Wed, 26 Aug 2026 08:45:00 -0400

DARE to PLAY Sildenafil Cream prescription dispensing and initial product revenue expected to commence in Q3 2026

SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience,

Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society

Wed, 26 Aug 2026 08:45:00 -0400

DARE to PLAY Sildenafil Cream prescription dispensing and initial product revenue expected to commence in Q3 2026

SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience,

Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society

Wed, 26 Aug 2026 08:45:00 -0400

DARE to PLAY Sildenafil Cream prescription dispensing and initial product revenue expected to commence in Q3 2026

SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience,

Daré Bioscience CEO discusses pipeline and commercial shift

Tue, 25 Aug 2026 08:55:21 -0400

Daré Bioscience, Inc. (NASDAQ: DARE) announced that President and CEO Sabrina Martucci Johnson participated in a Virtual Investor CEO Connect segment, discussing the company's transition from a development-stage biotech to a commercial-stage company.

Johnson highlighted the launch of Flora Sync LF5™ and preparations for DARE to PLAY™ Sildenafil Cream, a Section 503B compounded drug product not approved by the FDA, to begin generating revenue. She also described the company's efforts to build commercial infrastructure intended to support multiple products, including customer acquisition, provider engagement and market access.

On the pipeline side, Johnson referenced positive interim Phase 3 results for Ovaprene®, an investigational

Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

Tue, 25 Aug 2026 08:55:00 -0400

President & CEO, Sabrina Martucci Johnson, discusses the Company’s shift to commercial stage, upcoming revenue opportunities, Ovaprene’s positive interim Phase 3 results and what could drive value over the next 12–18 months

Access the segment here

SAN DIEGO, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, participated in a

Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

Tue, 25 Aug 2026 08:55:00 -0400

Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

Tue, 25 Aug 2026 08:55:00 -0400

Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

Tue, 25 Aug 2026 08:55:00 -0400

Form SCHEDULE 13G Dare Bioscience, Inc. Filed by: L1 Capital Global Opportunities Master Fund, Ltd.

Mon, 24 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260824/26968184.html

Form SCHEDULE 13G Dare Bioscience, Inc. Filed by: L1 Capital Global Opportunities Master Fund, Ltd.

Mon, 24 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260824/26968184.html